, Volume 27, Issue 11, pp 891–901 | Cite as

The Future of Health Technology Assessment in Healthcare Decision Making in Asia

  • Bong-Min Yang
Current Opinion


Most countries have healthcare resource constraints and it is easy to identify new health technologies as an area in need of resource management, particularly given that new health technologies usually increase rather than save costs. Resource constraints are even more noticeable in Asia than in other regions, with a comparatively greater speed of population aging and the development of health security systems. The healthcare industry and policy makers in Asia generally understand that rationing in healthcare delivery is inevitable and have come to accept health technology assessment (HTA) as a policy option.

The HTA policy framework is slowly penetrating Asia; South Korea was the first country to regulate the use of pharmacoeconomic evidence in drug reimbursement decision making. The South Korean HTA policy was initially a surprise in Asia in that the policy was suddenly introduced with a short period of preparation, but industry, researchers and policy makers both in- and outside of South Korea have come to accept it as necessary and logical.

Thailand and Taiwan have also taken steps towards using pharmacoeconomic evidence in HTA, while other Asian countries are planning to implement such policies. However, it could be some time before a legitimate pharmacoeconomic-based HTA policy is actually implemented in each country, and the course of action will vary depending on the policy culture, healthcare system and public trust in bureaucracy of each country.


National Health Insurance Health Technology Assessment Reimbursement Decision Health Technology Assessment Report Reimbursement List 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this article. The author has no conflicts of interest that are directly relevant to the content of this article.


  1. 1.
    Evidence-based decision making in Asia-Pacific health care systems of ten countries. 3rd Asia-Pacific ISPOR Conference; 2008 Sep 7-9; SeoulGoogle Scholar
  2. 2.
    Tarn YH, Hu S, Kamae I, et al. Health-care systems and pharmacoeconomic research in Asia-Pacific region. Value Health 2008 Mar; 11 Suppl. 1: 137–55CrossRefGoogle Scholar
  3. 3.
    ISPOR HTA Council Asia-Pacific, 3rd Asia-Pacific ISPOR Conference; 2008 Sep 7-9; SeoulGoogle Scholar
  4. 4.
    Drummond MF, Schwartz JS, Jonsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 2008 Summer; 24 (3): 244–58; discussion 362-8PubMedGoogle Scholar
  5. 5.
    Yang BM, Bae EY, Kim J. Economic evaluation and pharmaceutical reimbursement reform in South Korea’s National Health Insurance. Health Aff (Millwood) 2008 Jan-Feb; 27 (1): 179–87CrossRefGoogle Scholar
  6. 6.
    Health Insurance Review and Assessment Service. Guidelines for economic evaluation of pharmaceuticals in Korea. Seoul: HIRA, 2005Google Scholar
  7. 7.
    Health Insurance Review and Assessment Service. List of pharmaceuticals in national health insurance. Seoul: HIRA, 2006Google Scholar
  8. 8.
    Ministry of Health and Welfare. Implementation of positive list system policy. Seoul: Government of Korea, 2007Google Scholar
  9. 9.
    Kim S. Health Insurance Review and Assessment Service workshop. Seoul: HIRA, 2006 JanGoogle Scholar
  10. 10.
    Minutes from Health Insurance Reform Committee Meetings, Ministry of Health and Welfare, Government of Korea, 2004Google Scholar
  11. 11.
    HIRA report. Seoul: HIRA, 2007 (Data on file)Google Scholar
  12. 12.
    Special Panel Discussion Session on the Policy of Reevaluation of the Reimbursement Listed Drugs. Seoul: Daily-Pharm News, 2009 Jan 13Google Scholar
  13. 13.
    Yang BM, Kim CJ, Choi DH, et al. Cost-effectiveness of clopidogrel in acute coronary syndromes in South Korea. Seoul: Seoul National University, 2008Google Scholar
  14. 14.
    Department of Health. National health expenditure. Taipei: Government of Taiwan, 2006 [online]. Available from URL: ( [Accessed 2008 Aug 1]Google Scholar
  15. 15.
    Huang N. Health technology assessment issues in Taiwan [presentation]. Pricing and Reimbursement Evidence Board Meetings; 2008 Jun 10; BangkokGoogle Scholar
  16. 16.
    Tarn YH. The experience of HTA agency in Taiwan [presentation]. 2008 International HTA Symposium; 2008 Aug 11; TaipeiGoogle Scholar
  17. 17.
    Yang M-C. Health policy and planning in Taiwan [presentation]. 1st Asia-Pacific Conference in Health Policy and Planning in an Era of Emerging Technology and Cancer; 2008 Nov 18; Kuala LumpurGoogle Scholar
  18. 18.
    Chaiyakunapruk N. Health technology assessment in Thailand [presentation]. Pricing and Reimbursement Evidence Board Meetings; 2008 Jun 10; BangkokGoogle Scholar
  19. 19.
    WHO Statistical Information System (WHOSIS), 2008 [online]. Available from URL: ([Location].Members) [Accessed 2008 Aug 1]
  20. 20.
    Hanvoravongchai P. Health system and equity perspectives in health technology assessment. J Med Assoc 2008 Jun; 91 (2 Suppl.): 74S–87SGoogle Scholar
  21. 21.
    Wibulpolprasert S. The need for guidelines and the use of economic evidence in decision making in Thailand: lessons learnt from the development of the national list of essential drugs. J Med Assoc Thai 2008 June; 91 (2 Suppl.): 1S–3SGoogle Scholar
  22. 22.
    Teerawattananon Y. Health technology assessment in Thailand: turning a troubled teen into a successful adult. International Health Technology Assessment Symposium; 2008 Aug 1; TaipeiGoogle Scholar
  23. 23.
    English version of THTAG. J Med Assoc Thai 2008 Jun; 91 (2 Suppl.): S11–S65Google Scholar
  24. 24.
    Kapol N, Maitreemit P, Rapeepun C, et al. Making health technology assessment information available for decision making: the development of a Thai database. J Med Assoc Thai 2008 Jun; 91 (2 Suppl.): 8S–10SGoogle Scholar
  25. 25.
    Tangcharoensathien V, Kamolratanakul P. Making sensible rationing: the use of economic evidence and the need for methodological standards. J Med Assoc Thai 2008 Jun; 91 (2 Suppl.): 4S–7SGoogle Scholar
  26. 26.
    Doherty J, Kamae I, Lee KK, et al. What is next for pharmacoeconomics and outcomes research in Asia? Value Health 2004 Mar-Apr; 7 (2): 118–32PubMedCrossRefGoogle Scholar
  27. 27.
    Retherford R, Westley S, Choe M, et al. The future of population in Asia. Honolulu: University of Hawaii, 2002.Google Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.School of Public HealthSeoul National UniversitySeoulSouth Korea

Personalised recommendations